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eliminate in-stent restenosis in selected simple lesions (FIM. RAVEL trials). The aim of 
this study is to investigate the efficacy of SES in the treatment of bifurcation lesions. 
Methods: Since ld” April 2002 it is the policy of our institution to utilize the SES as a 
device of choice for all percutaneous interventions, with no clinical or anatomical exclu- 
sion criteria. The patients with bifurcation lesions are being included in this study. The fol- 
low-up angiography will be performed at 6 months after procedure. Results: Up to 161h 
August 2002, 44 patients with 44 bifurcation lesions have been treated with SES. The 
mean age was 61 years old and 13 patients (29.5%) were diabetic. All patients under- 
went SES deployment in both vessels. The baseline QCA results are present in the table. 
So far, there has been one target lesion revascularization 5 weeks after procedure, how- 
ever it is noteworthy that the restenosis occurred at the ostium of a side branch that was 
not covered with SES. The clinical outcomes and follow-up QCA results will be available 
at the time of presentation.Conclusions In this study, the impact of sirolimus-eluting 
stents on the outcome of patients with bifurcation lesions in the “real world” experience 
will be reported. 
Parent vessel side branch 
Pre reference diameter (mm) 2.84 - 0.56 2.31 - 0.54 
Pre minimum lumen diameter (mm) 0.76 - 0.59 0.65 - 0.50 
Post feference diameter (mm) 2.66 - 0.56 2.33 - 0.54 
Postminimum lumen diameter(mm) 2.36 -0.54 1.98 - 0.54 
1030-I 81 The Frequency and Consequences of Angiographic 
Aneurysms After Sirolimus-Eluting Stents: Results from 
SlRliJS 
Martin B. Leon, Jeffrey W. Moses, Giora Weiss, Paul S. Teirstein. Peter Fitzgerald, David 
R. Holmes, Jeffrey J. Popma. Cardiovascular Research Foundation, New York, NY 
Background: Angiographic aneurysms are observed after control bare metal stems 
(CS) in < 1% of pts and thusfar haven’t been associated with deleterious clinical out- 
comes. The marked anti-proliferative effects of sirolimus-eluting sterns (SES) raise con- 
cerns regarding potential vessel wall thinning and an increase in aneurysm formation. 
Methods: In the randomized double-blind SIRIUS trial (1058 pts), 8-month angiographic 
follow-up (FU) was obtained in 66% (702 pts). Angiographic aneurysms were defined as 
treatment site vessel diameter 2 1.5X the normal reference diameter (either at baseline 
or at FU) and all patients were assessed for clinical events (up to 9 months). 
Results: Aneurysms were found at FU in 6 pts (0.9%); 4 pts with CS (1.1%) and 2 pts 
with SES (0.6%). In the 4 CS aneurysms 0 FU, 2 were present at baseline and 
morhphology was fusiform ectasia in 2 (both multiple stents), and eccentric focal (<IO 
mm length) outpouching in 2 (1 proximal to RCA stent). In the 2 SES aneurysms @ FU, 
none were present at baseline and morphology was fusiform ectasia in 1 (3 SES after 
long RCA dissection) and eccentric focal outpouching in 1 (within RCA SES). In the 1 
case of SES focal outpouching, IVUS exam revealed.clear incomplete apposition at FU 
(flush apposition at baseline) with positive remodeling. Although 2 pts with angiographic 
aneurysms in CS pts had Res at FU, no pt in either group had adverse clinical events 
(death, MI. or stem thrombosis) during FU. 
Conclusions: Results from the SIRIUS angiographic analysis indicate that aneurysms at 
FU are (1) extremely infrequent (- 1%) with both CS and SES; (2) commonly were 
present at baseline and often are seen as diffuse fusiform ectasia; (3) are not associated 
with important clinical events (9 months FU). Thus, there are no objective findings to sug- 
gest that SES confer added risk of aneurysm formation and subsequent clinical events, 
1030-l 82 Platelet Activation After Stenting With Heparin-Coated 
Versus Noncoated Stents 
Paul A. Gurbel, Kevin P. Bliden, Bonnie L. Hi&t, Sinai Center for Thrombosis Research, 
Baltimore, MD 
Objectives: The purpose of the study was to investigate the effect of heparin coating on 
platelet activation following coronary artery stenbng. Background: In animal models hep- 
arin coating reduces platelet aggregation induced by coronary stenting. However, 
reduced platelet activation has never been demonstrated in humans. Methods: In a pro- 
spective randomized study of 50 consecutive elective patients, platelet activation was 
analyzed by measuring aggregation and surface receptor expression at baseline and at 2 
hours, 24 hours, 5 and 30 days following implantation of either heparin-coated or non- 
coated Bx velocity stent(s). Results: Platelet activation as measured by 24 hour expres- 
sion ( mean fluorescence intensity) of active glycoprotein (GP) Ilb/llla, and total GP llbi 
Illa. was decreased following implantation of a hepadn coated stent as compared to bare 
stents (10.3 f 6.1 vs 6.7 * 2.1, p=.O14 for active GPllb/llla and 382*101 vs 306+ 88, 
p=.Ol for total GPllb/llla). A trend at 30 days post-stentlng of lower total (383&150 vs 
296*86, ~~07) and active GP Ilb/llla expression (10.3i6.9 vs. 7.5k2.9, p=.15) were also 
observed with the heparin-coated stent. Aggregation and stimulated p-selectin did not 
differ between stent types. Conclusion: Elective stenting wtth a heparin-coated stent is 
associated with less early expression of GP Ilb/llla on circulating platelets as compared 
to revascularization with a bare stent of the same design. These findings have direct 
implications on the risk of subacute thrombosis and deserve further investigation 
1030-l 83 Sirolimus-Eluting Stent for the Treatment of Bypass 
Graft Disease: The Initial U.S. Experience 
Marco A. Costa, Jeffrey W. Moses, Martin B. Leon, Paul S. Teirstetn, Steven Yakubov, 
Andrew J. Carter, Tim A. Fischell, Paul Gilmore, Theodore A. Bass, University of Florida, 
Jacksonville, FL 
Background: Stenting has provided limited success in the treatment of saphenous vein 
grafts (SVG) as in-stent restenosis (ISR) and adverse clinical events remain a challenge. 
While brachytherapy has offered clear benefit in this high-risk population, outcomes 
remain suboptimal. The efficacy of Sirolimus-eluting stents in native coronary arteries is 
proven, however its application in bypass grafts remains to be determined. We report the 
first series of patients in the United States with graft disease treated with sirolimus-eluting 
stents as part of the compassionate use SECURE trial. 
Methods: Compassionate use of sirolimus-eluting stenting was indicated for patients 
with a serious disease or condition for which there was no acceptable alternative treat- 
ment available. To date, 80 patients have been enrolled in the SECURE study. Follow-up 
agiography will be repeated in all patients with prior brachytherapy failure. 
Results: Nineteen patients with bypass graft disease have been enrolled so far. Patient 
characteristics include: mean age 65 years, male 91%. prior myccardial infarction 55%, 
smokers 82%, diabetes 9%, hypertension 91% and hyperlipidemia 91%. Twenty-two per- 
cent presented with unstable angina. All patients had previous angioplasty. Seventeen 
lesions were treated in 15 grafts analyzed to date. Nine target vessels underwent previ- 
ous brachytherapy. Bypassed vessels were: RCA 29%, LAD 36%, Circumflex 29%. oth- 
ers 7%. Mean reference vessel diameter was 3.16mm, lesion length was 15mm. Mean of 
1.5 stents were implanted in each graft. There were no deaths up to 30 days in the first 
11 patients. Adjudicated in-hospital and a-month updated data will be presented. 
Conclusion: Implantation of sirolimus-eluting stents in high-risk patients is feasible. This 
may represent an important treatment option for patients with bypass graft disease. 
1030-l 84 Use of the Sirolimus Drug-Eluting Stent for Real World 
Coronary Lesions The Milan Experience: Results of the 
First 400 Lesions 
Vassilis Spanos Goran Stankovic, Flavio Airoldi, Matteo Montorfano, Nicola Corvaja. 
Francesco Liistro, Alaide Chieffo, Maryuri Segura, Davide Tavano, Carlo Di Mario, 
Antonio Colombo, Centro Cuore Columbus, Milan, Italy, San Raffaele Hospital, Milan, 
Italy 
Background: Positive results from the use of the Sirolimus drug-eluting stent 
(CYPHERTM, Cordis) in clinical trials addressing selected lesions have been published. 
We reporl our experience with the use of the Cypher stent in everyday clinical practice. 
Methods: We included all lesions treated with the Cypher stent in Milan between 15 of 
April and 30 of August 2002. Major adverse cardiac events (MACE) were defined as 
death, Q-wave myocardial infarction or target lesion revascularizatron. 
Results: Cypher stents were implanted in 217 patients (71% consecutive) to treat 418 
lesions. Three hundred fifty-three (84.5%) lesions were complex (ACClAHA classification 
82 or higher); 85 (20.3%) were in-stent restenosis and 42 (10.0%) chronic total occlu- 
sions. We utilized 2.2t1.6 Cypher stents per procedure (1.2~0.5 per lesion). Intravascu- 
lar ultrasound guidance was used in 67 (16.0%) lesions. The reference vessel size was 
2.8*0.5mm, the minimal lumen diameter (MLD) 0.79*0.48mm and the mean lesion 
length 18.5+13.8mm. 
The total length of Cypherstents used per lesion was 28.0+16.2mm. The maximum infla- 
tion pressure used was 15.7+3.4 atm and the balloon to artery ratio 1.1*0.3. The post- 
procedure MLD was 2.81*0.47mm, resulting in acute gain of 2.0*0.6mm. 
The clinical success rate was 99%. One patient required urgent coronary artery bypass 
surgery and died the next day and one had a Q-wave myocardial infarction during the 
procedure. 
Clinical follow-up at 1.720.5 months has been completed in 176 patients (97.8%) without 
detection of any other MACE. Six-month clinical follow-up will be available at the time of 
presentabon. Follow-up coronary angiography is planned for all patients nine months 
post-procedure and it is estimated to be accomplished in about 250 lesions at the time of 
presentation. Conclusions: The implantation of Cypher stents in “real world lesions”, 
aiming to completely cover the diseased segment, results in high stented vessel lengths. 
Thirly days complications are low without an increase in thrombosis, despite usage of 
long and multiple stents. We will see if follow-up results are in accordance with prior find- 
ings in less complex lesions. 
1030-l 85 Is There Any Arterial Toxic Effect After Overlapping 
Siroiimus-Eluting Stents? 
Alexandre A. Abizaid, Juan S. Munoz, Ana C. Seixas, Andrea S. Abizaid, Fausto Feres, 
Luiz A. Mattes, lbraim Pinto, Rodolfo Staico, Luiz F. Tanajura, Aurea J. Chaves, 
Marinella Centernero, Amanda Sousa, Gary S. Mints, Jose Eduardo M. Sousa, Institute 
Dante Pazzanese of Cardiology, Sao Paula, Brazil 
Background: Drug-eluting stents reduce first-time in-stent restenosis (ISR) and are 
being investigated as a treatment for ISR after bare-metal stenting. However, it remains 
unclear whether overlapping drug-eluting stents (and effectively doubling the drug dose) 
has a toxic effect on the vessel wall. 
Objective: The purpose of this study was to analyse the one-year IVUS findings after 2 
overlapping Sirolimus-eluting stems were implanted in patients with native artery ISR 
lesions. 
Methods: Cf 25 patients in the ISR Sirolimus registry, 8 had a lesion length requiring 2 
stents for full lesion coverage. Per protocol, these stents were implanted with a >l mm of 
overlap. Volumetric intravascular ultrasound (IVUS) was performed immediately and one 
year after implantation. 
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Results: The mean overlap length was 5.8kl.8 mm. There were no quantitative changes 
in IVUS measurements within the overlap segment (Table), and there was no case of 
late malapposition. 
Post l-year FU P value 
External elastic membrane volume (mn?) 61.8 * 14.6 58.2 * 13.6 0.6 
Lumen volume (mms) 38.1 * 14.3 36.9 * 14.5 0.8 
Stent volume (mm3, 38.1 * 14.3 38.1 f 14.3 1.0 
Plaque volume behind the stent (mn?) 23.8 * 5.8 20.1 * 5.7 0.2 
lntimal hyperplasia volume (mn?) l.li0.4 NA 
% intimal hyperplasia 3.4 NA 
Conclusions: There appears to be no deleterious effect on the arterial wall - quantitative 
changes in vessel wall geometry or late malapposition -when overlapping Sirolimus-elut- 
ing stents are implanted to treat ISR lesions. 
1030-l 86 The Effects of Sirolimus-Eluting Stems on In-Stent and 
Peri-Stent Restenosis: An Angiographic Subanalysis 
From the SIRIUS Trial 
Martin B. Leon, Jeffrey J. Popma, Steven Yakubov, William Bachinsky, Paul S. Teirstein, 
Tim A. Fischell. Lowell Satler, Mark Reisman. Jeffrey W. Moses, Cardiovascular 
Research FoundationlLenox Hill Hospital, New York, NY 
Background: Angiographic and IVUS findings from RAVEL indicated dramatic suppres- 
sion of neointimal hyperplasia within and around the sirolimus-eluting stent (SES) region. 
Methods: SIRIUS is a randomized double-blind study (1058 pts) comparing SES vs. 
control bare stems (CS) in more event-prone patients and more complex lesions. QCA 
analysis was performed at 8 months follow-up, independently examining late loss (LL) 
and binary restenosis (Res) confined to the in-stent region (ISR) and/or to the peri-stent 
regions (PSR = 5mm proximal or distal to the stent). 
Results: Angiographic findings 8 follow-up are shown in the table. The ratio of in-lesion 
to in-stent Res was 2.8 for SES vs. 1.0 for CS, indicating a much greater relative contri- 
bution of PSR to overall in-lesion Res with SES. The lack of complete suppression of 
neointima hyperplasia in the proximal PSR was most common in small/medium size yes- 
sels (tercile analysis) and in diabetics. 
Conclusions: SES in the SIRIUS trial (more complex patients and lesions) resulted in 
(1) almost complete abolition of LL within and immediately distal to the stent, and (2) a 
49% reduction in LL in the proximal PSR (28% reduction in prox PSR Res). Operator- 
induced PSR balloon injury may be contributory, suggesting that direct stenting, longer 
stent lengths, and lower stent deployment pressures should be evaluated. 
Follow-up SES(n=349) CS(n=353) P-Value 
LL (mm) ISR 0.17 1.00 <O.OOl 
PSR prox 0.17 0.33 <O.OOl 
PSR distal 0.04 0.24 <0.001 
RES (%) ISR 3.2 35.4 <O.OOl 
PSR prox 5.8 8.1 0.285 
PSR distal 2.0 7.2 0.002 
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1031-173 Receptor Activator of NF-kB (RANK) end Its Ligand 
RANK-L Coincide With Expression of Rapamycin 
Receptor FKBPl2 in Neointimal Dendritlc Cells 
Alexander Jaba Dirk Skowasch, Margaret Fomey Prescoti, Berndt LOderitz, Gerhard 
Bauriedel, University of Bonn, Bonn, Germany, Cardiovascular Disease Research, 
Novartis Comp., Summit, NJ 
Background: We recently reported the presence of dendritic cells (DC@ in postangio- 
plasty neointima and suggested their circulatory origin. The aim of the present study was 
to assess the mode of DC survival at the angioplasty site. Specifically, we sought to ana- 
lyze the presence of RANK whose activation by TNF-related ligands like RANK-L medi- 
ates anti-apoptotic effects promoting DC survival. In addition, we assessed the 
expresSion of FKBPlP, the primary intracellular rapamycin receptor, as rapamycin may 
induce DC apoptosis. 
Methods: The expression of RANK, RANK-L and FKBP12 was detected by immunohis- 
tochemistry in rat carotid arteries at 7 and 28 days post balloon angioplasty (n=8 per 
time). OX-62 and SIOO immunostaining was used to identify DCs. In addition, neointimal 
cell types and apoptosis ware characterized by transmission electron microscopy (TEM). 
Results: At day 7, the vast majority of neointimal cells were identified as DCs by OX-62 
and SIOO immunolabeling. TEM demonstrated cells with typical ultrastructural features 
of DCs, whereas apoptosis was observed in ~5% of all neointimal cells. Both RANK and 
RANK-L revealed similar expression profiles as those of OX-62 and SlOO. In serial sec- 
tions, extensive immunoreactivity for FKBPlP was frequently found with neointimal cells 
at this time point. However, at day 28, neointimal signaling for RANK and its ligand was 
preserved along the luminal surface, coincident with OX-62 and SlOO expression. 
Accordingly, TEM analysis revealed DCs exclusively in the apical neointima, while basal 
areas contained smooth muscle-like cells. Neointimal apoptosis was cl% at this time. 
lmmunoreaction of FKBPIP was detectable in luminal neointima with DC aggregation. Of 
note, media and adventitia consistently revealed no immunolabeling for RANK, RANK-L, 
FKBP12 or DCs at both time points. 
Conclusions: The present data identify viable DCs as novel cellular component involved 
in early neointima formation, and suggest DC-specific RANK expressIon, co-localized 
with its ligand RANK-L, to promote their survival. Since neointimal DCs strongly express 
FKBPlP, rapamycin may selectively interfere with neointimal DC accumulation post 
angioplasty. 
1031-174 Endovascular Irradiation Chronically Impairs 
Endothelium-Dependent Relaxation in Noninjured Pig 
Coronary Arteries 
Keith A. Robinson, Jinsheng Li, Bunken Ebato, Jianhua Cui, John Todd, Nicolas A. 
Chronos, Hector DeLeon, American Cardiovascular Research Institute, Norcross, GA 
Background: Endovascular brachytherapy inhibits restenosis after coronary interven- 
tion. To avoid geographic miss, normal artery segments adjacent to the intervention site 
are also irradiated. The effect of irradiation on vasomotor function of normal coronary 
arteries has not been studied. Methods: Vasomotor responses of pig coronary arteries 
to substance P, Ca2+ ionophore A23187, and sodium nitroprusside (SNP) were deter- 
mined 1 mo after sham (n=6) or active irradiation (RAD. n=l2; 20Gy p) and in non-instru- 
mented controls (n=8). Endothelial morphology and superoxide anion (0;) production 
were also studied. Results: Segments of radiated arteries were enlarged and exhibited 
perivascular fibrosis. Contraction to PGFZ, was similar across the groups (3.88*0.78g 
control, 3.25a0.6g sham, 3.48+0.42g RAD). However. PGF,,-induced contraction after 
nitric oxide synthase (NOS) inhibition with L-NAME was lower in RAD than sham 
(2.89*0.34g vs. 4.87+0.25g; P<O.O5). Contraction to KCI was decreased, relaxation to 
substance P and A23187 was abolished, and relaxation to SNP was potentiated in RAD. 
After NOS blockade with L-NAME, inhibition of dose-response relaxation to substance P 
was less marked in RAD than sham or control. Scanning electron microscopy of RAD 
showed -50% endothelial coverage with numerous adherent leukocytes; platelets were 
adherent in non-endothelialized regions. lmmunohistochemical staining of tissue sec- 
tions confirmed the presence of both endothelial cells and numerous leukocytes at the 
luminal surface. O;, production of RAD was significantly higher than sham (437r37.3 
RLU/s/mg vs. 126k11.6 RLU/s/mg, PcO.01). Conclusions: 1 mo after endovascular 
brachytherapy, pig coronaries had impaired endothelium-dependent relaxation, partial 
endothelial desquamation, adherent inflammatory cells and platelets, and increased O-; 
production. These results suggest that radiation induced both endothelial and smooth 
muscle cell dysfunction which persisted at 1 mo. Augmented 0, production associated 
with a pronounced inflammatory response may explain at least in part, the delayed 
effects of endovascular irradiation on coronary artery vasomotor function. 
1031-175 Chronic Stent-Induced Injury and Inflammation Results 
in Sustained Activation of the Cell Cycle in the Porcine 
Model 
Meenakshi Aaaarwal, Philip S. Tsao, Greg Kopia. Alec Glassford, Alan C. Yeung, Fermin 
Tio, Andrew J. Carter, Providence/St. Vincent’s Medical Center, Portland, OR, Stanford 
University, Palo Alto, CA 
The long-term processes of arterial repair are incompletely characterized though 
believed to be completed by 28 days in the porcine coronary model. The purpose of this 
study was to evaluate the chronic vascular response to bare metal stents on regulatory 
proteins of the cell cycle and to provide correlation with histological events. Methods: 
Fifty-three pigs underwent placement of 54 stems in the coronary arteries with histologic 
and Western blot (PCNA and CDC 2) analysis at 3, 30, 90 or 180 days. Histological eval- 
uation included vessel injury, strut associated inflammation and morphometric analysis of 
the arterial wall. Results: 
